Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dovitinib + docetaxel
- Development stage
- Phase 2
- Lead developer
- Allarity Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Dovitinib + docetaxel is a combination of two anticancer agents used in investigational and clinical settings for the treatment of various cancers. Dovitinib is an orally active small molecule inhibitor that targets multiple receptor tyrosine kinases (RTKs) involved in tumor growth and angiogenesis, including those implicated in acute myeloid leukemia and multiple myeloma. Docetaxel is a semisynthetic taxane antineoplastic agent that promotes microtubule assembly and stabilizes microtubules by preventing their depolymerization, thereby inhibiting cell division and inducing apoptosis. This combination leverages dovitinib’s multi-targeted kinase inhibition with docetaxel’s anti-mitotic effects to enhance anticancer efficacy[1][2][5].
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FLT3 (Fms related receptor tyrosine kinase 3)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)TUBB (Tubulin (alpha and beta subunits))RTK (Receptor Tyrosine Kinase)
Beyond the preview
Go deeper on Dovitinib + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dovitinib + docetaxel.